Antiphospholipid Syndrome News

 

  • Rheumatologist Dr. Doruk Erkan talks about Antiphospholipid Syndrome (APS), the disorder that caused my stroke, in this Q&A with the Hospital for Special Surgery. Read it to learn more about APS. – Dr. Doruk Erkan, Rheumatologist (April 6, 2011)
  • A Catalyst for Antiphospholipid Syndrome Research. APS ACTION is coordinating international efforts to study this rare and potentially fatal autoimmune disorder. The treatment of the serious, potentially fatal autoimmune clotting disorder antiphospholipid syndrome (APS) has, in general, been empiric and based on various approaches to inhibit the clotting system. Despite many clinical studies and progress in patient outcomes, the field has nevertheless lacked a solid foundation upon which to base decision making and the development of novel approaches–The Rheumatologist (March 2011)
  • Antiphospholipid syndrome: endocrinologic manifestations and organ involvement – PubMed (Feb. 2001) From: Seminars in Thrombosis and Hemostasis Journal. Recet clinical experience concluded that APS should be considered in any patient with adrenal insufficiency even in the absence of other thrombotic manifestations. It is also advisable, the researchers found, to assess aPL in the blood of patients presenting with pituitary insufficiency. Further studies are needed to clarify the relationship between aPL and thyroid disorders and diabetes mellitus.
  • Antiphospholipid Syndrome Clinical Research Task Force Report – Med Connect (February 8, 2011) The report urges an international collaboration to design and conduct clinical trials of APS patients.